U.S. Markets close in 35 mins
  • S&P 500

    3,395.59
    -5.38 (-0.16%)
     
  • Dow 30

    27,525.21
    -160.17 (-0.58%)
     
  • Nasdaq

    11,426.17
    +67.23 (+0.59%)
     
  • Russell 2000

    1,591.85
    -13.36 (-0.83%)
     
  • Crude Oil

    39.48
    +0.92 (+2.39%)
     
  • Gold

    1,909.10
    +3.40 (+0.18%)
     
  • Silver

    24.47
    +0.05 (+0.18%)
     
  • EUR/USD

    1.1818
    +0.0004 (+0.0355%)
     
  • 10-Yr Bond

    0.7780
    -0.0230 (-2.87%)
     
  • Vix

    33.05
    +0.59 (+1.82%)
     
  • GBP/USD

    1.3056
    +0.0035 (+0.2703%)
     
  • USD/JPY

    104.4780
    -0.3570 (-0.3405%)
     
  • BTC-USD

    13,618.15
    +510.92 (+3.90%)
     
  • CMC Crypto 200

    270.08
    +8.79 (+3.36%)
     
  • FTSE 100

    5,728.99
    -63.02 (-1.09%)
     
  • Nikkei 225

    23,485.80
    -8.54 (-0.04%)
     

Biofrontera AG plans mediation to resolve (legal) disputes

Biofrontera AG
·1 min read

Leverkusen, Germany, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or the “Biofrontera-Group”), an international biopharmaceutical company, today has reached a mutual agreement with Mr. Wilhelm K.T. Zours and Deutsche Balaton AG on the key elements of a mediation agreement. The completion of the mediation agreement is expected today.

Within the framework of the mediation process, which is to commence shortly, an experienced and renowned mediator will be called in to find solutions for the settlement of disputes as well as disagreements on personnel and strategic corporate matters.

Mr. Zours is chairman of the supervisory board and majority shareholder of Deutsche Balaton AG and is as such an indirect major shareholder of the Company. Between the Company on one side and Deutsche Balaton AG together with other companies in which Mr. Zours holds a majority interest on the other side, various legal disputes are pending in Germany and one legal dispute in the USA.

Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen

ISIN: DE0006046113
WKN: 604611

Contact: Biofrontera AG
Tel.: +49 (0214) 87 63 2 0, Fax.: +49 (0214) 87 63 290
E-mail: ir@biofrontera.com